{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 55 of 129', \"The sponsor's medical expert must be notified if a subject receives any of these medications\", 'during the trial.', '9.6 Rescue treatment', 'If medically necessary (i.e., to control intolerable AD symptoms), rescue treatment for AD', 'may be provided to trial subjects at the discretion of the investigator. If possible, investigators', 'should attempt to limit the first step of rescue therapy to topical medications, and escalate to', 'systemic medications only for subjects who do not respond adequately after at least 14 days', 'of topical treatment. The subject will be monitored for signs of local or systemic TCS toxicity', 'and the safety and appropriateness of continued use will be supervised by site staff. For', 'reporting of AD flares see Section 10.3.1.4.', 'Subjects who receive topical rescue treatment (higher potency TCS: Europe Class >3; US', 'Class <4) will continue IMP treatment.', 'If a subject receives rescue treatment with systemic corticosteroids or non-steroidal systemic', 'immunosuppressive drugs (cyclosporine, methotrexate, mycophenolate-mofetil azathioprine,', 'etc.), IMP will be immediately discontinued (see Section 9.7.2, reasons for temporary', 'discontinuation of IMP). After the treatment with these medications is completed, IMP may', \"be resumed if deemed appropriate by the investigator and sponsor's medical expert, but not\", 'sooner than 5 half-lives after the last dose of systemic rescue medication.', 'Investigators should make every attempt to conduct efficacy and safety assessments (at least', 'disease severity scores [IGA and EASI], concomitant medications/procedures, and AEs)', 'immediately before administering any rescue treatment. An unscheduled visit may be used for', 'this purpose, if necessary.', 'In the primary efficacy analyses, subjects who receive topical or systemic rescue treatment', 'during the treatment periods will be considered as non-responders.', '9.7 Dose modification and IMP discontinuation rules', '9.7.1 Reasons for permanent discontinuation of IMP', 'Subjects will be permanently discontinued from IMP in the event of:', 'Anaphylactic reaction or other severe systemic reaction to IMP injection.', \"An AE that, in the opinion of the investigator or sponsor's medical expert,\", 'contraindicates further dosing.', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 56 of 129', 'Diagnosis of a malignancy during the trial, excluding carcinoma in situ of the', 'cervix, or localised squamous or basal cell carcinoma of the skin.', 'Evidence of pregnancy.', 'Any infection that is opportunistic, such as active tuberculosis and other', 'infections whose nature or course may suggest an immuno-compromised', 'status.', 'Severe laboratory abnormalities:', 'ALT and/or AST values >3xULN with total bilirubin >2xULN', '(unless elevated bilirubin is related to Gilbert-Meulengracht', 'Syndrome).', 'Confirmed AST and/or ALT >5xULN (for more than 2 weeks).', 'Subjects who in the opinion of the subject or investigator have unacceptable treatment effect', 'of IMP in combination with TCS therapy may discontinue treatment permanently and enter', 'the safety follow-up period.', 'Refer to Section 8.5 for details on the handling of subject discontinuation and Panel 3 for', 'assessments to be performed at an early termination visit for subjects who discontinue IMP', 'permanently.', '9.7.2 Reasons for temporary discontinuation of IMP', 'IMP dosing may be temporarily suspended in the event of:', 'Other intercurrent illnesses or major surgery.', 'An infection that requires parenteral treatment with antibiotic, antifungal,', 'antiviral, anti-parasitic, or anti-protozoal agents.', 'Treatment with systemic corticosteroids or non-steroidal', 'immunosuppressive/immunomodulating medications (e.g., cyclosporine,', 'methotrexate, azathioprine, mycophenolate-mofetil, Janus kinase inhibitors,', 'dupilumab or other biologics). IMP dosing may be resumed after the', 'medication leading to suspension of IMP is discontinued; see Section 9.6 for', 'details regarding re-initiation of IMP after discontinuation of systemic rescue', 'treatment.', 'A decision to discontinue IMP temporarily or to reinstitute IMP treatment must be discussed', \"with sponsor's medical expert. However, the investigator may suspend trial treatment at any\", 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}